An Honest Broker, Not a Shop

What this desk brokers

The name is deliberate and it means what an honest broker means in policy work: someone who lays out the full range of what is known, including the parts that undercut the enthusiasm, and leaves the choosing to somebody else. This desk brokers information about peptides. It does not broker peptides. Nothing here is for sale, nothing here is a referral, and no supplier, clinic or pharmacy is named or recommended anywhere on the site.

The editorial question it exists to answer is narrower than it looks. A reader who encounters ipamorelin, GHK-Cu, PT-141 and tirzepatide in the same forum thread will reasonably assume they belong to one family of things. They do not. They belong to four separate pharmacological classes with four separate evidence bases and four different legal statuses. Sorting them is the whole job.

So the organising unit here is class, not compound. Each brief opens with a plain-English summary that a non-specialist can read in a minute, then goes to the underlying pharmacology, then to the published studies, then to what people report and what the documented cautions are, and finally to where that class sits relative to the other three. Every quantitative claim carries a bracketed number pointing to a source on the references page.

How a class brief is assembled

Each brief is composed from an already-audited body of literature for that compound, not assembled ad hoc from search results. The citation list on this site is fixed, numbered and checked against that source material before publication, which is why the numbers in brackets are stable and why a reader will not find a study cited here that is missing from the reference list.

Three editorial rules govern the writing. First, quantitative claims carry citations — percentages, participant counts, durations, half-lives and effect sizes all trace to a numbered source. Second, community-reported effects are labelled as anecdotal, not clinical evidence, kept visibly separate from trial findings, and never attached to a dose. Third, doses appear only as descriptions of what a cited study administered, never as a suggestion of what anyone should take.

The desk also states negative results as prominently as positive ones. A Phase 2 trial that missed its primary endpoint is reported as a failed trial ^[3]. A safety meta-analysis that found a significant biliary signal is reported with the confidence interval attached ^[20]. A hair-growth trial that tested a combination product rather than the single compound is described as testing a combination ^[8]. Where a literature leans heavily on one research group, that is said plainly.

Where the brief stops

This desk is not a clinic, a pharmacy, a laboratory or a source of medical advice, and several kinds of question are outside what it can honestly answer.

It cannot say what any compound will do for a particular person. Trials describe populations, and a relative risk or a mean percentage change is a statement about a group, not a prediction about a reader. It cannot advise on dosing, protocols, cycling or combinations, and it does not publish that material even where community consensus exists — the consensus is not evidence. It cannot verify what is inside a vial, which is a limitation worth taking seriously, because unverified purity is a documented concern for more than one compound briefed here.

It also stops where the literature stops. Where a compound has no validated human pharmacokinetics, that absence is reported rather than filled in with mechanism-flavoured speculation. Where a claim comes from cell culture or a rodent model, the species is named. Where an argument about clinical meaningfulness is unresolved, both sides are stated and neither is settled on the reader's behalf.

Anyone weighing a decision about their own health should be talking to a licensed clinician who can see their history. This desk exists for the step before that conversation: understanding what the literature actually says, so the conversation starts from something real.